Identification of a 1.2 Kb cDNA fragment from a region on 9p21 commonly deleted in multiple tumor types.

Chromosome band 9p21 is a frequent target of homozygous deletion in many tumor types. Putative tumor suppressor genes, CDKN2A (p16), p14(ARF) and CDKN2B (p15), were localized to 9p21. However, there have been reports that suggest that there may be other genes targeted for inactivation in the region. We have developed a method to search for transcribed sequences within large genomic regions. We tested our approach in a 100-kilobase region on 9p21, which is 40 kilobases telomeric to CDKN2A. The method, termed expressed sequence selection (ESS), resulted in the isolation of genomic fragments known to be from 9q21 that are homologous to transcribed sequences. One fragment was used to obtain a 1.2 kilobase cDNA. The sequence of the 5' half of the cDNA was almost identical to exons 3-5 of the MTAP gene, which maps to chromosome band 9p21. The 3' portion of the cDNA had sequence homology to the ALA gene, which maps to chromosome arm 9q. Using Northern blot analysis, the 1.2 Kb cDNA identified several widely expressed transcripts ranging from 1 Kb to 8.5 Kb and displayed a complex pattern of alternative splicing in which certain exons of the 1.2 Kb cDNA are excluded from some of the splice products. Using cancer tissue Northern blots, we could show that all of the transcripts are absent from a leukemia cell line and a lung cancer cell line (K562, A549) with homozygous, genomic deletions within chromosome band 9p21. In addition, the 7 Kb transcript is also absent from two additional tumor cell lines (Molt4, a leukemia derived cell line, and in G361, a melanoma derived cell line) with homozygous deletions. Further investigation will determine whether the difference in the expression pattern between the 7 Kb transcript compared with the other sized transcripts could be due to specific targeting for alteration in certain tumor types.

[1]  D. Quelle,et al.  Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Takahashi,et al.  Contribution of Chromosome 9p21‐22 Deletion to the Progression of Human Renal Cell Carcinoma , 1995, Japanese journal of cancer research : Gann.

[3]  J. Rowley,et al.  Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[4]  O. Olopade,et al.  Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. , 1992, Genomics.

[5]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[6]  S. Scherer,et al.  Delineation of multiple deleted regions in 7q in myeloid disorders , 1999, Genes, chromosomes & cancer.

[7]  T. Savarese,et al.  Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. , 1996, Cancer genetics and cytogenetics.

[8]  W. Foulkes,et al.  Loh and mutation analysis of CDKN2 in primary human ovarian cancers , 1995, International journal of cancer.

[9]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[10]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[11]  A. Brenner,et al.  Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. , 1995, Cancer research.

[12]  R. Chaganti,et al.  Homozygous Deletions and Loss of Expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors , 1995, Genes, chromosomes & cancer.

[13]  W. Franklin,et al.  Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. , 1997, Cancer research.

[14]  O. Olopade,et al.  Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. , 1992, Cancer research.

[15]  J. Stephenson,et al.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia , 1982, Nature.

[16]  M. Boavida,et al.  Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions. , 1997, Cancer genetics and cytogenetics.

[17]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[18]  Carissa A. Sanchez,et al.  Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. , 1996, Oncogene.

[19]  O. Olopade,et al.  Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. , 1994, Cancer research.

[20]  H. Koeffler,et al.  Alterations of the p15, p16,and p18 genes in osteosarcoma. , 1996, Cancer genetics and cytogenetics.

[21]  Ashutosh Kumar Singh,et al.  Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. , 1994, Cancer research.

[22]  J. Rowley,et al.  A method for the rapid sequence-independent amplification of microdissected chromosomal material. , 1992, Genomics.

[23]  W. Farrell,et al.  Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. , 1997, Cancer research.

[24]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[25]  X. Estivill,et al.  Retention of the CDKN2A locus and low frequency of point mutations in primary and metastasic cutaneous malignant melanoma , 1998, International journal of cancer.

[26]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[27]  D. Dexter,et al.  5'-deoxy-5'-methylthioadenosine phosphorylase--II. Role of the enzyme in the metabolism and antineoplastic action of adenine-substituted analogs of 5'-deoxy-5'-methylthioadenosine. , 1983, Biochemical pharmacology.

[28]  C. Sherr,et al.  Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.

[29]  O. Olopade,et al.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.